[
    {
        "pregunta": "1. Why should screening for ILD not be limited only to patients with identified risk factors in systemic autoimmune rheumatic diseases (SARDs)?",
        "respuesta": "El tamizaje para enfermedad pulmonar intersticial (EPI) en pacientes con enfermedades reumáticas autoinmunes sistémicas (ERAS) **no debería limitarse solo a aquellos con factores de riesgo identificados** porque, aunque ciertos rasgos clínicos se asocian con un mayor riesgo de desarrollar EPI, la ausencia de dichos factores no excluye la posibilidad de que el paciente desarrolle enfermedad pulmonar. Por ello, el tamizaje debe realizarse en un marco de toma de decisiones compartida entre el reumatólogo y el paciente, considerando las particularidades individuales de cada caso.\n\nEn resumen, la recomendación es que el tamizaje sea personalizado y no exclusivamente focalizado en pacientes con factores de riesgo, para asegurar una detección oportuna y adecuada de la EPI en la población con ERAS.",
        "contexto": [
            "are not the only choice in this setting. Leukotriene inhibitors should not be used to treat manifestations aside from asthma and sinonasal disease. Recommendation: For patients with EGPA, we conditionally recommend obtaining an echocardiogram at the time of diagnosis. Cardiac involvement is the major cause of diseaserelated mortality in EGPA Recommendation: For patients with EGPA, we conditionally recommend using the Five-Factor Score to guide therapy. The Five-Factor Score (FFS), first",
            "by a greater number of randomized trials than are currently available in EGPA. All of the recommendations made for these 3 diseases are conditional, which indicates that there are settings in which the evidence is not strong or an alternative is a reasonable consideration. These recommendations should not be used by any agency to restrict access to therapy or require that certain therapies be utilized prior to other therapies. The physicians on the Voting Panel were primarily rheumatologists,",
            "or overlap antibodies (eg, PM-Scl, Ku, Ro52) are at increased risk for ILD progression. Thus, screening must be tailored to an individual patient, recognizing the need for shared decision-making. Although most people with SSc and many people with IIM warrant screening, it is not necessary to screen all people with RA or SjD. The Voting Panel voted on recommendations for people at higher risk of ILD within each disease. Although defining the magnitude of risk within diseases was beyond the scope",
            "<li>These disease features have been identiﬁed as placing a person at increased risk for developing ILD; however, the absence of these risk factors does not preclude the development of ILD in patients with these SARDs. Screening for ILD should be performed in shared decision-making with the rheumatologist and patient. As such, screening for ILD should not necessarily be limited only to those with these risk factors. CCP, cyclic citrullinated peptide; ILD, interstitial lung disease; MDA-5, MDA-5",
            "(see ungraded position statement and recommendation on this topic). Recommendation: For patients with EGPA who have experienced relapse with nonsevere disease manifestations (asthma and/or sinonasal disease) while receiving methotrexate, azathioprine, or mycophenolate mofetil, we conditionally recommend adding mepolizumab over switching to another agent. For patients with EGPA with active asthma, inhaled therapies should be maximized prior to increasing systemic immunosuppressive therapy."
        ]
    },
    {
        "pregunta": "2. Which screening methods are conditionally recommended against for ILD in SARD patients?",
        "respuesta": "La información proporcionada no incluye detalles específicos sobre métodos de tamizaje que estén recomendados de manera condicional en contra para la enfermedad pulmonar intersticial (EPI) en pacientes con enfermedades reumáticas autoinmunes sistémicas (ERAS). Por lo tanto, no es posible ofrecer una respuesta confiable sobre este tema basándose en los datos disponibles.",
        "contexto": [
            "|Recommendation: For patients with EGPA and high serum IgE levels who have experienced relapse with nonsevere disease manifestations (asthma and/or sinonasal disease) while receiving methotrexate, azathioprine, or mycophenolate mofetil, we conditionally recommend adding mepolizumab over adding omalizumab.|27|Very low|\n|Other considerations| | |",
            "|Recommendation: For patients with EGPA who have experienced relapse with nonsevere disease manifestations (asthma and/or sinonasal disease) while receiving methotrexate, azathioprine, or mycophenolate mofetil, we conditionally recommend adding mepolizumab over switching to another agent.|26|Very low|",
            "(see ungraded position statement and recommendation on this topic). Recommendation: For patients with EGPA who have experienced relapse with nonsevere disease manifestations (asthma and/or sinonasal disease) while receiving methotrexate, azathioprine, or mycophenolate mofetil, we conditionally recommend adding mepolizumab over switching to another agent. For patients with EGPA with active asthma, inhaled therapies should be maximized prior to increasing systemic immunosuppressive therapy.",
            "while receiving methotrexate, azathioprine, or mycophenolate mofetil, we conditionally recommend adding mepolizumab over adding omalizumab. The published evidence on omalizumab, an anti-IgE antibody, in EGPA has been limited. Therefore, even for a patient with high serum IgE levels, mepolizumab is the preferred choice based on evidence from the randomized controlled trial Other considerations Recommendation: For patients with newly diagnosed EGPA receiving leukotriene inhibitors, we",
            "2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases  National Scleroderma Foundation  Pulmonary Fibrosis Foundation  CAE  Boston University Medical Center  Johns Hopkins University School of Medicine  Global Healthy Living Foundation      F4AB96C66964635F924057BA1BB25AD2 10.1002/art.42860 Submitted for publication August 21, 2023;"
        ]
    },
    {
        "pregunta": "3. What systemic manifestations in mixed connective tissue disease (MCTD) are associated with higher ILD risk?",
        "respuesta": "Las manifestaciones sistémicas en la enfermedad mixta del tejido conectivo (EMTC) asociadas con un mayor riesgo de enfermedad pulmonar intersticial (EPI) incluyen:\n\n- Lesiones ulcerantes  \n- Disfagia  \n- Fenómeno de Raynaud  \n- Otras características clínicas o de laboratorio propias de esclerosis sistémica\n\nEstas manifestaciones constituyen signos de mayor riesgo para desarrollar EPI en pacientes con EMTC según la información disponible.",
        "contexto": [
            "(oral)</strong><br><strong>Varicella</strong><br><strong>Zoster</strong><br><strong>Yellow fever</strong> | <strong>Systemic lupus erythematosus</strong><br><strong>Sjögren's syndrome</strong><br><strong>Systemic sclerosis</strong><br><strong>Idiopathic inflammatory myopathies</strong><br><strong>Mixed connective tissue disease</strong><br><strong>Undifferentiated connective tissue disease</strong><br><strong>Antiphospholipid antibody syndrome</strong> |",
            "|Idiopathic inflammatory myopathies|• Male sex,²² higher body mass index • Anti-synthetase (Jo-1, PL7, PL12, EJ, OJ, KS, Ha, Zo), anti–MDA-5, anti-Ku, anti-Pm/Scl, anti-Ro52 antibody positivity • Mechanic’s hands, arthritis/arthralgia|\n|Mixed connective tissue disease|• ulcerating lesions²⁴ • Dysphagia, Raynaud phenomenon • Other systemic sclerosis clinical or laboratory features|",
            "arthritis (RA), systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM; including polymyositis, dermatomyositis, immune-mediated necrotizing myopathy, and anti-synthetase syndrome), mixed connective tissue disease (MCTD), and Sjögren disease (SjD) are at particularly high risk. 1 There are no existing guidelines for ILD screening for people with SARDs. This guideline was developed to provide recommendations for the screening of ILD in people with SARDs (RA, SSc, IIM, MCTD, and SjD)",
            "2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases  National Scleroderma Foundation  Pulmonary Fibrosis Foundation  CAE  Boston University Medical Center  Johns Hopkins University School of Medicine  Global Healthy Living Foundation      F4AB96C66964635F924057BA1BB25AD2 10.1002/art.42860 Submitted for publication August 21, 2023;",
            "including both deep vein thromboses and pulmonary emboli Recommendations and ungraded position statements for EGPA EGPA is characterized by diverse features, including asthma/ allergic rhinitis, peripheral and tissue eosinophilia, and vasculitis. As these clinical features can potentially have differing responses to treatment, the management approach is typically based on a patient's disease features and severity. The recommendations presented here focus primarily on the use of"
        ]
    },
    {
        "pregunta": "4. Why is screening with chest radiography conditionally recommended against in patients with SARDs at risk for ILD?",
        "respuesta": "Se recomienda de manera condicional **no usar la radiografía de tórax como método de tamizaje** para enfermedad pulmonar intersticial (EPI) en pacientes con enfermedades reumáticas autoinmunes sistémicas (ERAS) con riesgo aumentado de desarrollar EPI debido a que la radiografía de tórax tiene **baja sensibilidad (58%-64%)**, lo que limita su utilidad para detectar de manera temprana y adecuada la enfermedad pulmonar en esta población. Por ello, se considera que la radiografía de tórax no es una herramienta eficaz para el tamizaje rutinario de EPI en pacientes con ERAS en riesgo.",
        "contexto": [
            "evidence from five observational studies suggests that PFTs alone may be insufficient to detect ILD among patients with newly diagnosed SARDs. For people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with chest radiography. Three studies indicated a low sensitivity of chest radiography (58%-64%), limiting utility as a screening test for ILD. For people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with",
            "obtaining an MRI in this setting. MRI could be considered in circumstances where the clinician and patient differ in their assessment of whether the disease is stable. In adults with active or stable AS receiving any treatment, we conditionally recommend against obtaining repeat spine radiographs at a scheduled interval (e.g., every 2 years) as a standard approach (new, PICO 70). In adults with active or stable nonradiographic axial SpA on any treatment, we conditionally recommend against",
            "are conditionally recommended for the screening of ILD in people with these SARDs, whereas PFTs, HRCT chest, and ambulatory desaturation testing are conditionally recommended for the monitoring of people with SARD-ILD. There are limited to no roles for chest radiography, 6MWD, bronchoscopy, or surgical lung biopsy for the routine screening or monitoring of people with SARD-ILD. We provide guidance on the risk factors and frequency of testing to evaluate for the development of ILD in people with",
            "by a greater number of randomized trials than are currently available in EGPA. All of the recommendations made for these 3 diseases are conditional, which indicates that there are settings in which the evidence is not strong or an alternative is a reasonable consideration. These recommendations should not be used by any agency to restrict access to therapy or require that certain therapies be utilized prior to other therapies. The physicians on the Voting Panel were primarily rheumatologists,",
            "|Recommendation: For patients with EGPA who have experienced relapse with nonsevere disease manifestations (asthma and/or sinonasal disease) while receiving methotrexate, azathioprine, or mycophenolate mofetil, we conditionally recommend adding mepolizumab over switching to another agent.|26|Very low|"
        ]
    },
    {
        "pregunta": "5. How does the progression and monitoring frequency of rheumatoid arthritis-associated ILD (RA-ILD) differ from that of other SARD-ILDs?",
        "respuesta": "La progresión de la enfermedad pulmonar intersticial asociada a artritis reumatoide (EPI-AR) suele ser más lenta en comparación con otras EPI relacionadas con enfermedades reumáticas autoinmunes sistémicas (ERAS). Respecto a la frecuencia de monitoreo, se sugiere realizar pruebas de función pulmonar (PFTs) cada 6 a 12 meses en pacientes con EPI-AR estable, aunque situaciones específicas, como el patrón de neumonía intersticial usual (UIP) —que confiere un peor pronóstico— pueden requerir un monitoreo más frecuente (cada 3 a 6 meses), ajustado al juicio clínico.\n\nEn resumen:\n\n- **Progresión:** La EPI-AR progresa típicamente más lentamente que otras EPI asociadas a ERAS.  \n- **Monitoreo:** Se recomienda hacer PFTs cada 6-12 meses, con monitoreo más frecuente en casos de patrón UIP, empeoramiento sintomático o funcional, o presencia de autoanticuerpos relacionados con progresión rápida.\n\nEsta estrategia busca detectar cambios tempranos y ajustar el tratamiento según la evolución individual del paciente.",
        "contexto": [
            "2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases  National Scleroderma Foundation  Pulmonary Fibrosis Foundation  CAE  Boston University Medical Center  Johns Hopkins University School of Medicine  Global Healthy Living Foundation      F4AB96C66964635F924057BA1BB25AD2 10.1002/art.42860 Submitted for publication August 21, 2023;",
            "2023 American College of Rheumatology (ACR) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease      AB9490E2CBB5C4579E5F0776547A04FE ACR Board of Directors on 12 August 2023. These recommendations are included in a full manuscript, pending peer review, which was submitted for publication in Arthritis & Rheumatology and Arthritis Care and Research.  Table 1. Summary of recommendations for screening of SARD-ILD Summary",
            "for the first year, then less frequently once stable. RA-ILD typically progresses more slowly than the other SARDs; however, a usual interstitial pneumonia (UIP) pattern confers a worse prognosis and may warrant more frequent monitoring. Monitoring those with RA-ILD with PFTs every 6 to 12 months is suggested, recognizing that specific situations may warrant more frequent monitoring (3-6 months). SjD-ILD tends to be milder than other types of SARD-associated ILD; however, those with the Ro52",
            "10.1002/art.42860 Submitted for publication August 21, 2023; accepted in revised form April 9, 2024.  INTRODUCTION Interstitial lung disease (ILD) is characterized by inflammation and/or fibrosis of the lung parenchyma and is a significant cause of morbidity and mortality in people with systemic autoimmune rheumatic diseases (SARDs). Although people with SARDs are at risk for developing ILD in general, those with rheumatoid arthritis (RA), systemic sclerosis (SSc), idiopathic inflammatory",
            "than other types of SARD-associated ILD; however, those with the Ro52 antibody can progress quickly. SjD can occur as an overlap condition with anti-synthetase syndrome, SSc, and RA. More frequent monitoring, based on physician judgment, should be performed in patients with symptom worsening, a UIP pattern, presence of autoantibodies associated with rapidly progressive disease (eg, anti-MDA-5), and worsening PFTs. People with MCTD and prominent features of SSc or IIM may benefit from more"
        ]
    },
    {
        "pregunta": "6. How does disease activity in SARDs influence the monitoring frequency of associated ILD?",
        "respuesta": "La actividad de la enfermedad en las enfermedades reumáticas autoinmunes sistémicas (ERAS) influye directamente en la frecuencia del monitoreo de la enfermedad pulmonar intersticial (EPI) asociada. Específicamente, en pacientes con EPI estable, las pruebas de función pulmonar (PFTs) se recomiendan realizar cada 6 a 12 meses. Sin embargo, en situaciones con mayor actividad o factores de mal pronóstico, como la presencia del patrón radiológico de neumonía intersticial usual (UIP), empeoramiento sintomático o funcional, o la detección de autoanticuerpos vinculados a progresión rápida, el monitoreo debe ser más frecuente (cada 3 a 6 meses). \n\nPor lo tanto, un mayor nivel de actividad o características que sugieren progresión más agresiva de la EPI justifican una vigilancia más estrecha para ajustar oportunamente el tratamiento.  \n\nEsta recomendación busca equilibrar la detección temprana de cambios en la enfermedad pulmonar con la minimización de pruebas innecesarias en casos estables.",
        "contexto": [
            "2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases  National Scleroderma Foundation  Pulmonary Fibrosis Foundation  CAE  Boston University Medical Center  Johns Hopkins University School of Medicine  Global Healthy Living Foundation      F4AB96C66964635F924057BA1BB25AD2 10.1002/art.42860 Submitted for publication August 21, 2023;",
            "2023 American College of Rheumatology (ACR) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease      AB9490E2CBB5C4579E5F0776547A04FE ACR Board of Directors on 12 August 2023. These recommendations are included in a full manuscript, pending peer review, which was submitted for publication in Arthritis & Rheumatology and Arthritis Care and Research.  Table 1. Summary of recommendations for screening of SARD-ILD Summary",
            "activity disease Patient participants expressed a strong desire that their physicians discuss family planning \"early and often,\" including before planning of pregnancy. Discussion with patients should include information on medications and impact of disease activity, autoantibodies, and organ system abnormalities on maternal and fetal health. In rare situations with significant disease-related damage, such as pulmonary arterial hypertension, renal dysfunction, heart failure, or other severe",
            "10.1002/art.42860 Submitted for publication August 21, 2023; accepted in revised form April 9, 2024.  INTRODUCTION Interstitial lung disease (ILD) is characterized by inflammation and/or fibrosis of the lung parenchyma and is a significant cause of morbidity and mortality in people with systemic autoimmune rheumatic diseases (SARDs). Although people with SARDs are at risk for developing ILD in general, those with rheumatoid arthritis (RA), systemic sclerosis (SSc), idiopathic inflammatory",
            "of severe PsA disease include the presence of ≥1 of the following: a poor prognostic factor (erosive disease, elevated levels of inflammation markers such as C-reactive protein or erythrocyte sedimentation rate attributable to PsA), long-term damage that interferes with function (e.g., joint deformities, vision loss), highly active disease that causes major impairment in quality of life (i.e., active psoriatic inflammatory disease at many sites [including dactylitis, enthesitis] or"
        ]
    },
    {
        "pregunta": "7. Why is the 6-minute walk distance (6MWD) test conditionally recommended against for routine monitoring in patients with SARD-ILD?",
        "respuesta": "Se recomienda de manera condicional **no usar la prueba de la distancia caminada en 6 minutos (6MWD)** para el monitoreo rutinario en pacientes con enfermedad pulmonar intersticial (EPI) asociada a enfermedades reumáticas autoinmunes sistémicas (ERAS) porque:\n\n- No existe evidencia publicada que respalde el uso de 6MWD como prueba de tamizaje o monitoreo para EPI en esta población.  \n- La 6MWD puede verse afectada por otras manifestaciones clínicas de las ERAS, como artritis y enfermedad cardíaca, que limitan la movilidad y confunden la interpretación de la prueba.  \n- Los pacientes reportan que la 6MWD frecuentemente no refleja sus síntomas reales ni la capacidad funcional para realizar actividades diarias.  \n- Su utilidad está mejor establecida en contextos específicos, como la evaluación pretrasplante pulmonar, hipertensión pulmonar, y en pacientes con limitaciones que les impiden realizar pruebas de función pulmonar (PFT).  \n\nPor estas razones, la guía condiciona en contra de su uso para monitoreo rutinario de EPI en ERAS, recomendando reservarla para situaciones clínicas particulares donde sea más informativa.",
        "contexto": [
            "risk of developing ILD, we conditionally recommend against screening with 6MWD. The Literature Review Team found no published evidence regarding 6MWD as a screening test for ILD. Rather, it is used for evaluation for lung transplantation and for monitoring in those with pulmonary hypertension. In people with SARDs, the 6MWD can be impacted by other SARD manifestations that affect mobility including arthritis and cardiac disease. The Patient Panel felt the 6MWD frequently did not reflect",
            "(73.6%) of chest radiography relative to HRCT chest for identifying ILD among patients with inflammatory rheumatic diseases. For people with SARD-ILD, we conditionally recommend against monitoring with 6MWD. There was no evidence to support or oppose using 6MWD in the monitoring of people with SARD-ILD. 6MWD can be impacted by other health factors, such as arthritis and cardiac disease. Patients reported that 6MWD often did not reflect activities of daily living or function in daily life. If",
            "disease. The Patient Panel felt the 6MWD frequently did not reflect symptoms and may not reflect functional status or ability to perform activities of daily living. For people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with ambulatory desaturation testing. The Literature Review Team found no published evidence regarding the use of ambulatory desaturation testing as a screening test for ILD in SARDs. Given feasibility concerns in rheumatology",
            "did not reflect activities of daily living or function in daily life. If patients without confounding health factors can perform the test, it can be a useful marker to follow disease progression. 6MWD is important in the monitoring of patients pre-lung transplantation, those with pulmonary hypertension, and those unable to perform PFTs. For people with SARD-ILD, we conditionally recommend against monitoring with bronchoscopy. There was no published evidence. The panel was not in favor of",
            "| For people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with 6MWD. |\n| For people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with chest radiography. |\n| For people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with ambulatory desaturation testing. |"
        ]
    },
    {
        "pregunta": "8. What are the recommended screening tests for ILD in patients with SARDs at increased risk?",
        "respuesta": "Las pruebas de tamizaje recomendadas para la enfermedad pulmonar intersticial (EPI) en pacientes con enfermedades reumáticas autoinmunes sistémicas (ERAS) con riesgo aumentado incluyen:\n\n- **Pruebas de función pulmonar (PFTs)**, que abarcan espirometría, medición de volúmenes pulmonares y difusión de monóxido de carbono (DLCO). Estas pruebas están recomendadas de manera condicional para el tamizaje inicial de EPI en esta población.\n\n- **Tomografía computarizada de alta resolución (HRCT) de tórax**, recomendada de manera condicional como herramienta fundamental para detectar EPI precoz y caracterizar su patrón.\n\nPor el contrario, la **radiografía de tórax** se recomienda de manera condicional en contra como método de tamizaje debido a su baja sensibilidad (58%-64%) para detectar la EPI.\n\nEn resumen, el tamizaje debe estar basado en PFTs y HRCT en pacientes con ERAS considerados con riesgo aumentado, dentro de un marco de decisión compartida entre el reumatólogo y el paciente.",
        "contexto": [
            "2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases  National Scleroderma Foundation  Pulmonary Fibrosis Foundation  CAE  Boston University Medical Center  Johns Hopkins University School of Medicine  Global Healthy Living Foundation      F4AB96C66964635F924057BA1BB25AD2 10.1002/art.42860 Submitted for publication August 21, 2023;",
            "2023 American College of Rheumatology (ACR) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease      AB9490E2CBB5C4579E5F0776547A04FE ACR Board of Directors on 12 August 2023. These recommendations are included in a full manuscript, pending peer review, which was submitted for publication in Arthritis & Rheumatology and Arthritis Care and Research.  Table 1. Summary of recommendations for screening of SARD-ILD Summary",
            "or early in pregnancy in women with SLE or SLE-like disorders, Sjögren's syndrome, systemic sclerosis, and rheumatoid arthritis. Given the relative persistence and unchanged titers of these antibodies, we strongly recommend against repeating the test during pregnancy. Patients with scleroderma renal crisis. Most diseasespecific recommendations for RMD pregnancy management focus on presence of underlying SLE or positive aPL. One aspect of disease in systemic sclerosis, however, is of particular",
            "to support the frequency of testing was limited, The Core Team and Voting Panel preferred a risk-based approach. We suggest that most people with SSc, IIM, and MCTD with SSc features should have ILD screening tests at presentation. We also suggest that people with IIM have myositis-specific antibody testing to screen for the presence of high-risk ILD-associated antibodies (anti-synthetase and anti-MDA-5 antibodies). Although we do not suggest that all patients with RA and SjD be screened for",
            "on the panel routinely perform ambulatory desaturation testing in their offices. It is difficult to recommend a specific interval of ambulatory desaturation testing, and there is no evidence to support this guidance. DISCUSSION This guideline provides recommendations to clinicians for ILD screening and monitoring in people with RA, SSc, IIM, MCTD, and SjD. PFTs (including spirometry, lung volumes, and DLCO) and HRCT chest are conditionally recommended for the screening of ILD in people with"
        ]
    },
    {
        "pregunta": "9. How often are PFTs suggested for monitoring ILD progression in patients with idiopathic inflammatory myopathy-associated ILD (IIM-ILD) and systemic sclerosis-associated ILD (SSc-ILD) during the first year?",
        "respuesta": "La frecuencia sugerida para realizar pruebas de función pulmonar (PFTs) durante el primer año en pacientes con enfermedad pulmonar intersticial asociada a miopatía inflamatoria idiopática (EPI-MII) y a esclerosis sistémica (EPI-ES) es **cada 3 a 6 meses**. Posteriormente, si la enfermedad está estable, se recomienda un monitoreo con menor frecuencia. \n\nEste enfoque reconoce la necesidad de un seguimiento más estrecho temprano en el curso de la enfermedad y en pacientes con actividad pulmonar significativa.",
        "contexto": [
            "instead. Some patients may need more frequent monitoring, especially if symptoms change, and these suggestions should not be used to inform reimbursement decisions. There is substantial clinical variation from patient to patient that may affect testing frequency. For people with IIM-ILD and SSc-ILD, we suggest PFTs for monitoring every 3 to 6 months for the first year, then less frequently once stable. More frequent monitoring is needed early in the course of disease and in patients with active",
            "between rheumatology and pulmonology. Thus, some recommendations will comment on potential variations in practice between these specialties. For people with SARD-ILD, we conditionally recommend monitoring with PFTs. PFTs (spirometry, volumes, and DLCO) provide objective data that are helpful in following patients over time. Patients saw benefit in an objective test to help assess disease stability or progression. Although PFTs can reassure both patient and clinician when they are stable,",
            "perform PFTs, or those with associated pulmonary hypertension. For people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with bronchoscopy. Based on very low-certainty evidence from two observational studies, One retrospective observational (very low-certainty evidence) study provided indirect evidence for this recommendation. Suggestions for frequency of screening Evidence to support the frequency of testing was limited, The Core Team and Voting",
            "on the panel routinely perform ambulatory desaturation testing in their offices. It is difficult to recommend a specific interval of ambulatory desaturation testing, and there is no evidence to support this guidance. DISCUSSION This guideline provides recommendations to clinicians for ILD screening and monitoring in people with RA, SSc, IIM, MCTD, and SjD. PFTs (including spirometry, lung volumes, and DLCO) and HRCT chest are conditionally recommended for the screening of ILD in people with",
            "<ul>\n<li>PFTs included spirometry, lung volumes, and DLCO. DLCO, diffusion capacity for carbon monoxide; HRCT chest, high-resolution computed tomography of the chest; IIM, idiopathic inflammatory myopathies; ILD, interstitial lung disease; MCTD, mixed connective tissue disease; PFT, pulmonary function test; RA, rheumatoid arthritis; SARD, systemic autoimmune rheumatic disease; SjD, Sjögren disease; SSc, systemic sclerosis; 6MWD, 6-minute walk test distance.</li>\n</ul>"
        ]
    },
    {
        "pregunta": "10. What monitoring methods are conditionally recommended against for ILD progression in patients with SARDs-ILD?",
        "respuesta": "Los métodos de monitoreo que se recomiendan de manera condicional **en contra** para la progresión de la enfermedad pulmonar intersticial (EPI) en pacientes con enfermedades reumáticas autoinmunes sistémicas (ERAS) incluyen:\n\n- **Prueba de la distancia caminada en 6 minutos (6MWD):** Se desaconseja su uso para monitoreo rutinario porque no hay evidencia que respalde su utilidad en esta población, además puede ser afectada por otras manifestaciones clínicas de las ERAS, como artritis y enfermedad cardíaca, dificultando la interpretación de resultados.\n\n- **Radiografía de tórax como método de tamizaje:** Aunque no es un método de monitoreo propiamente dicho, se recomienda de forma condicional en contra su uso para detección de EPI debido a su baja sensibilidad (58%-64%).\n\n- **Broncoscopia para monitoreo:** Se recomienda condicionalmente en contra el uso de broncoscopia para el seguimiento de la EPI en pacientes con ERAS.\n\nEn resumen, los métodos condicionalmente desaconsejados incluyen la 6MWD, la radiografía de tórax para tamizaje, y la broncoscopia como herramienta de monitoreo, dada la evidencia limitada y las limitaciones en su capacidad para evaluar adecuadamente la progresión de la EPI en este contexto.",
        "contexto": [
            "2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases  National Scleroderma Foundation  Pulmonary Fibrosis Foundation  CAE  Boston University Medical Center  Johns Hopkins University School of Medicine  Global Healthy Living Foundation      F4AB96C66964635F924057BA1BB25AD2 10.1002/art.42860 Submitted for publication August 21, 2023;",
            "2023 American College of Rheumatology (ACR) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease      AB9490E2CBB5C4579E5F0776547A04FE ACR Board of Directors on 12 August 2023. These recommendations are included in a full manuscript, pending peer review, which was submitted for publication in Arthritis & Rheumatology and Arthritis Care and Research.  Table 1. Summary of recommendations for screening of SARD-ILD Summary",
            "between rheumatology and pulmonology. Thus, some recommendations will comment on potential variations in practice between these specialties. For people with SARD-ILD, we conditionally recommend monitoring with PFTs. PFTs (spirometry, volumes, and DLCO) provide objective data that are helpful in following patients over time. Patients saw benefit in an objective test to help assess disease stability or progression. Although PFTs can reassure both patient and clinician when they are stable,",
            "on the panel routinely perform ambulatory desaturation testing in their offices. It is difficult to recommend a specific interval of ambulatory desaturation testing, and there is no evidence to support this guidance. DISCUSSION This guideline provides recommendations to clinicians for ILD screening and monitoring in people with RA, SSc, IIM, MCTD, and SjD. PFTs (including spirometry, lung volumes, and DLCO) and HRCT chest are conditionally recommended for the screening of ILD in people with",
            "recommend against monitoring with 6MWD. For people with SARDs-ILD, we conditionally recommend against monitoring with bronchoscopy. For people with IIM-ILD and SSc-ILD, we suggest PFTs for monitoring every 3-6 months rather than either shorter or longer intervals, for the first year, then less frequently once stable. For people with RA-ILD, SjD-ILD, and MCTD-ILD, we suggest PFTs for monitoring every 3-12 months rather than shorter or longer intervals, for the first year, then less frequently"
        ]
    },
    {
        "pregunta": "11. What factors influence the frequency of monitoring in patients with SARD-ILD?",
        "respuesta": "Los factores que influyen en la frecuencia del monitoreo en pacientes con enfermedad pulmonar intersticial (EPI) asociada a enfermedades reumáticas autoinmunes sistémicas (ERAS) son:\n\n- **Actividad de la enfermedad pulmonar:** En pacientes con EPI estable, se recomienda realizar pruebas de función pulmonar (PFTs) cada 6 a 12 meses. En cambio, en casos con mayor actividad o progresión, el monitoreo debe ser más frecuente (cada 3 a 6 meses).\n\n- **Patrón radiológico:** La presencia del patrón de neumonía intersticial usual (UIP), que se asocia a peor pronóstico, justifica mayor frecuencia de seguimiento.\n\n- **Cambios clínicos o funcionales:** Empeoramiento sintomático o funcional debe aumentar la frecuencia del monitoreo para detectar cambios tempranos.\n\n- **Detección de autoanticuerpos vinculados a progresión rápida:** La identificación de autoanticuerpos relacionados con evolución rápida de la enfermedad justifica vigilancia más estrecha.\n\n- **Tipo específico de EPI y fase de la enfermedad:** En pacientes con EPI asociada a miopatía inflamatoria idiopática (IIM-ILD) o esclerosis sistémica (SSc-ILD), se sugieren PFTs cada 3 a 6 meses durante el primer año, disminuyendo la frecuencia posteriormente si la enfermedad está estable.\n\n- **Preferencias del paciente y juicio clínico:** Se enfatiza la toma de decisiones compartida, considerando las circunstancias individuales.\n\nEn resumen, la frecuencia del monitoreo se adapta según la actividad de la enfermedad, criterios pronósticos, hallazgos clínicos y radiológicos, así como el tipo y evolución de la EPI en cada paciente con ERAS.",
        "contexto": [
            "2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases  National Scleroderma Foundation  Pulmonary Fibrosis Foundation  CAE  Boston University Medical Center  Johns Hopkins University School of Medicine  Global Healthy Living Foundation      F4AB96C66964635F924057BA1BB25AD2 10.1002/art.42860 Submitted for publication August 21, 2023;",
            "Additionally, we did not have any available evidence to examine the relationship between frequency of screening or monitoring and subsequent outcomes. Furthermore, there was a lack of evidence regarding the effects of screening or monitoring on specific subpopulations, such as racial and ethnic minority groups. Finally, we were unable to include other important affected patient groups because the scope of the guideline focused on diseases associated with higher risk of developing ILD. Pediatric",
            "active underlying SARD warrant more frequent monitoring. Pulmonologists generally see more progressive than long-standing, stable disease and prefer more frequent monitoring. Similarly, the Patient Panel expressed that there is \"nothing worse than being missed\" and strongly preferred more frequent testing to be reassured that their disease is stable. Because the guideline's target population included people with SARDs who have stable ILD as well as those with progressive ILD, it was important",
            "2023 American College of Rheumatology (ACR) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease      AB9490E2CBB5C4579E5F0776547A04FE ACR Board of Directors on 12 August 2023. These recommendations are included in a full manuscript, pending peer review, which was submitted for publication in Arthritis & Rheumatology and Arthritis Care and Research.  Table 1. Summary of recommendations for screening of SARD-ILD Summary",
            "instead. Some patients may need more frequent monitoring, especially if symptoms change, and these suggestions should not be used to inform reimbursement decisions. There is substantial clinical variation from patient to patient that may affect testing frequency. For people with IIM-ILD and SSc-ILD, we suggest PFTs for monitoring every 3 to 6 months for the first year, then less frequently once stable. More frequent monitoring is needed early in the course of disease and in patients with active"
        ]
    },
    {
        "pregunta": "12. In what clinical situations might ambulatory desaturation testing be considered for patients with SARDs?",
        "respuesta": "La realización de una prueba de desaturación ambulatoria en pacientes con enfermedades reumáticas autoinmunes sistémicas (ERAS) **podría considerarse en situaciones clínicas específicas**, tales como:\n\n- Cuando los pacientes presentan **calidad inadecuada en las pruebas de función pulmonar (PFTs)** o son incapaces de realizarlas.  \n- En la evaluación de pacientes con **hipertensión pulmonar asociada**.  \n- En contextos donde la prueba sea factible, particularmente en prácticas pulmonares o modelos interdisciplinarios de cuidado compartido, donde se dispone de los recursos para efectuarla adecuadamente.  \n- En casos seleccionados, siempre dentro de una toma de decisiones compartida entre el equipo clínico y el paciente.\n\nSin embargo, dado que la prueba puede tener limitaciones en pacientes con fenónemo de Raynaud (problemas con la precisión del sensor de pulso en el dedo) y dificultades operativas en consultorios de reumatología, su uso no está recomendado para tamizaje rutinario en todos los pacientes con ERAS.\n\nEn resumen, la prueba de desaturación ambulatoria se considera principalmente en pacientes con indicios o condiciones que dificultan la evaluación estándar de la función pulmonar o que presentan complicaciones pulmonares asociadas, y no como un test de tamizaje universal.",
        "contexto": [
            "between the application of this clinical assessment by rheumatologists and pulmonologists. Testing for ambulatory desaturation is inexpensive and informs a patient's need for supplemental oxygen. However, evaluation of ambulatory desaturation is not routine practice for many rheumatologists, and there may be operational challenges in performing ambulatory desaturation testing in some rheumatology offices. Pulmonologists on the panel routinely perform ambulatory desaturation testing in their",
            "test for ILD in SARDs. Given feasibility concerns in rheumatology outpatient practices, routine ambulatory desaturation testing was not recommended as a screening test. Within pulmonary outpatient practices and/or interdisciplinary models of shared care, ambulatory desaturation testing is more feasible and can be more easily offered in selected patients such as those with inadequate PFT quality, those who are unable to perform PFTs, or those with associated pulmonary hypertension. For people",
            "disease. The Patient Panel felt the 6MWD frequently did not reflect symptoms and may not reflect functional status or ability to perform activities of daily living. For people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with ambulatory desaturation testing. The Literature Review Team found no published evidence regarding the use of ambulatory desaturation testing as a screening test for ILD in SARDs. Given feasibility concerns in rheumatology",
            "vary based on individual disease presentation and shared decision-making with each patient. It was challenging for this group to reach consensus on the recommendation for ambulatory oxygen desaturation testing and the frequency of this testing. In people with Raynaud phenomenon, oxygen desaturation testing using a finger probe may not be accurate and, thus, may lead to the inappropriate prescription of supplemental oxygen. In such cases, ear or forehead probes offer potential for greater",
            "on the panel routinely perform ambulatory desaturation testing in their offices. It is difficult to recommend a specific interval of ambulatory desaturation testing, and there is no evidence to support this guidance. DISCUSSION This guideline provides recommendations to clinicians for ILD screening and monitoring in people with RA, SSc, IIM, MCTD, and SjD. PFTs (including spirometry, lung volumes, and DLCO) and HRCT chest are conditionally recommended for the screening of ILD in people with"
        ]
    },
    {
        "pregunta": "13. How do the recommendations differ between screening and monitoring strategies for ILD in patients with systemic autoimmune rheumatic diseases?",
        "respuesta": "Las recomendaciones para las estrategias de **tamizaje** y de **monitoreo** de la enfermedad pulmonar intersticial (EPI) en pacientes con enfermedades reumáticas autoinmunes sistémicas (ERAS) presentan diferencias importantes en función de la etapa clínica y los objetivos de evaluación:\n\n---\n\n### 1. **Tamizaje de EPI en ERAS**\n\n- **Objetivo:** Detectar precozmente la EPI en pacientes con ERAS, incluso antes de que aparezcan síntomas o signos clínicos evidentes.\n\n- **Población:** No debe limitarse únicamente a pacientes con factores de riesgo identificados, ya que la ausencia de estos no excluye el desarrollo de EPI.\n\n- **Pruebas recomendadas de forma condicional:**\n  - **Pruebas de función pulmonar (PFTs):** Incluyen espirometría, volúmenes pulmonares y DLCO.\n  - **Tomografía computarizada de alta resolución (HRCT) de tórax:** Considerada fundamental para la detección precoz y caracterización del patrón de EPI.\n\n- **Pruebas recomendadas en contra de forma condicional:**\n  - **Radiografía de tórax:** Debido a su baja sensibilidad (58%-64%) para detectar EPI, no se recomienda para tamizaje rutinario.\n  - **Prueba de la distancia caminada en 6 minutos (6MWD):** No hay evidencia suficiente para su uso en tamizaje.\n  - **Broncoscopia:** No recomendada para detección.\n\n---\n\n### 2. **Monitoreo de EPI en ERAS**\n\n- **Objetivo:** Evaluar la progresión de la enfermedad pulmonar en pacientes diagnosticados para ajustar el tratamiento y detectar deterioro temprano.\n\n- **Frecuencia del monitoreo:**\n  - En EPI estable, se recomienda realizar **PFTs cada 6 a 12 meses**.\n  - En enfermedad activa o con factores de peor pronóstico (por ej., patrón UIP, empeoramiento sintomático o funcional, presencia de autoanticuerpos vinculados a progresión rápida), se sugiere un monitoreo más frecuente **cada 3 a 6 meses**.\n  - En subtipos específicos como EPI asociada a miopatía inflamatoria idiopática (IIM-ILD) y esclerosis sistémica (SSc-ILD), se recomienda PFTs cada 3 a 6 meses durante el primer año.\n\n- **Pruebas recomendadas en contra de forma condicional para monitoreo:**\n  - **6MWD:** Limitada utilidad en monitoreo rutinario debido a confusión con manifestaciones extrapulmonares.\n  - **Radiografía de tórax y broncoscopia:** También desaconsejadas para seguimiento.\n\n- **Consideraciones adicionales:**\n  - El monitoreo se adapta según la actividad y características clínicas, radiológicas y serológicas de cada paciente.\n  - La toma de decisiones debe ser compartida entre médico y paciente.\n\n---\n\n### **Resumen de diferencias clave**\n\n| Aspecto                     | Tamizaje                                    | Monitoreo                                  |\n|----------------------------|---------------------------------------------|--------------------------------------------|\n| **Propósito**               | Detección precoz                            | Seguimiento y evaluación de progresión    |\n| **Población objetivo**      | Pacientes con ERAS, independiente de factores de riesgo | Pacientes diagnosticados con EPI           |\n| **Pruebas principales**     | PFTs y HRCT de tórax                        | PFTs (frecuencia variable según actividad)|\n| **Pruebas no recomendadas** | Radiografía de tórax, 6MWD, broncoscopia  | 6MWD, radiografía de tórax, broncoscopia  |\n| **Frecuencia**              | No definida; detección única o según riesgo| Cada 6-12 meses en estable; cada 3-6 meses si activa o mayor riesgo |\n| **Factores que modifican frecuencia** | No aplican directos, pero se considera factor riesgo para tamizaje| Patrón radiológico, síntomas, autoanticuerpos, evolución clínica |\n\n---\n\n**En conclusión,** el tamizaje se centra en la identificación temprana de EPI usando principalmente PFTs y HRCT y evitando pruebas con baja sensibilidad. En cambio, el monitoreo se basa principalmente en PFTs repetidas con frecuencias adaptadas a la actividad y riesgo de progresión de la enfermedad, desaconsejando pruebas con utilidad limitada o afectadas por comorbilidades extrapulmonares. La toma de decisiones debe ser personalizada y compartida en ambos escenarios.",
        "contexto": [
            "2023 American College of Rheumatology (ACR) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease      AB9490E2CBB5C4579E5F0776547A04FE ACR Board of Directors on 12 August 2023. These recommendations are included in a full manuscript, pending peer review, which was submitted for publication in Arthritis & Rheumatology and Arthritis Care and Research.  Table 1. Summary of recommendations for screening of SARD-ILD Summary",
            "2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases  National Scleroderma Foundation  Pulmonary Fibrosis Foundation  CAE  Boston University Medical Center  Johns Hopkins University School of Medicine  Global Healthy Living Foundation      F4AB96C66964635F924057BA1BB25AD2 10.1002/art.42860 Submitted for publication August 21, 2023;",
            "by a greater number of randomized trials than are currently available in EGPA. All of the recommendations made for these 3 diseases are conditional, which indicates that there are settings in which the evidence is not strong or an alternative is a reasonable consideration. These recommendations should not be used by any agency to restrict access to therapy or require that certain therapies be utilized prior to other therapies. The physicians on the Voting Panel were primarily rheumatologists,",
            "|Recommendation: For patients with EGPA who have experienced relapse with nonsevere disease manifestations (asthma and/or sinonasal disease) while receiving methotrexate, azathioprine, or mycophenolate mofetil, we conditionally recommend adding mepolizumab over switching to another agent.|26|Very low|",
            "(see ungraded position statement and recommendation on this topic). Recommendation: For patients with EGPA who have experienced relapse with nonsevere disease manifestations (asthma and/or sinonasal disease) while receiving methotrexate, azathioprine, or mycophenolate mofetil, we conditionally recommend adding mepolizumab over switching to another agent. For patients with EGPA with active asthma, inhaled therapies should be maximized prior to increasing systemic immunosuppressive therapy."
        ]
    },
    {
        "pregunta": "14. How does the combination of HRCT and PFTs compare to PFTs alone for screening patients at increased risk of ILD?",
        "respuesta": "La combinación de tomografía computarizada de alta resolución (HRCT) de tórax junto con pruebas de función pulmonar (PFTs) es recomendada **de manera condicional** para el tamizaje de pacientes con enfermedades reumáticas autoinmunes sistémicas (ERAS) que tienen mayor riesgo de enfermedad pulmonar intersticial (EPI), en comparación con la realización únicamente de PFTs.\n\nEsta recomendación se basa en evidencia de muy baja certeza, pero sugiere que la HRCT tiene una sensibilidad significativamente mayor (95.7%) para la detección de EPI con extensión pulmonar ≥20%, en contraparte a la sensibilidad más limitada de las PFTs solas.\n\nPor lo tanto, el uso conjunto de HRCT y PFTs ofrece una mejor capacidad para detectar precozmente la EPI en pacientes en riesgo, en comparación con la realización exclusiva de pruebas funcionales pulmonares.",
        "contexto": [
            "statement. HRCT chest, high-resolution computed tomography of the chest; ILD, interstitial lung disease; PICO, population, intervention, comparison and outcome; PFT, pulmonary function test; SARD, systemic autoimmune rheumatic disease; 6MWD, 6-minute walk test distance.</li>",
            "statement. HRCT chest; high-resolution computed tomography of the chest; ILD, interstitial lung disease; PICO, population, intervention, comparison, and outcomes; PFT, pulmonary function test; SARD, systemic autoimmune rheumatic disease; 6MWD, 6-minute walk test distance.</li>",
            "<ul>\n<li>PFTs included spirometry, lung volumes, and DLCO. DLCO, diffusion capacity for carbon monoxide; HRCT chest, high-resolution computed tomography of the chest; IIM, idiopathic inflammatory myopathies; ILD, interstitial lung disease; MCTD, mixed connective tissue disease; PFT, pulmonary function test; RA, rheumatoid arthritis; SARD, systemic autoimmune rheumatic disease; SjD, Sjögren disease; SSc, systemic sclerosis; 6MWD, 6-minute walk test distance.</li>\n</ul>",
            "66% specific), despite very low certainty of evidence (one observational study), For people with SARDs at increased risk of developing ILD, we conditionally recommend screening with HRCT chest over history and physical examination or PFTs alone. Very low-certainty evidence suggests that the HRCT chest has a sensitivity of 95.7% and specificity of 63.8% for the detection of ILD (≥20% extent of lung involvement). Low-certainty evidence from five observational studies suggests that PFTs alone may",
            "|Conditionally recommend HRCT chest over PFTs|Low|8|24|\n|Conditionally recommend HRCT chest and PFTs over PFTs alone|Very low|9|34|\n|Conditionally recommend against bronchoscopy|Very low|10|40|\n|Strongly recommend against surgical lung biopsy|Very low|11|46|</p>"
        ]
    },
    {
        "pregunta": "15. What are the advantages and limitations of using PFTs for monitoring ILD progression in SARD patients?",
        "respuesta": "Las pruebas de función pulmonar (PFTs), que incluyen espirometría, medición de volúmenes pulmonares y difusión de monóxido de carbono (DLCO), son **condicionalmente recomendadas para el monitoreo de la progresión de la enfermedad pulmonar intersticial (EPI) en pacientes con enfermedades reumáticas autoinmunes sistémicas (ERAS)**. \n\n**Ventajas:**\n\n- Proporcionan **datos objetivos** útiles para evaluar la estabilidad o progresión de la EPI a lo largo del tiempo.  \n- Los pacientes valoran que las PFTs les ayudan, junto con sus médicos, a monitorear la evolución de la enfermedad y tomar decisiones terapéuticas.  \n- Permiten detectar cambios tempranos en la función pulmonar que pueden indicar progresión o mejoría de la EPI.  \n- Son pruebas estandarizadas y ampliamente accesibles.  \n- Se sugiere realizar PFTs con una frecuencia adaptada según la actividad y riesgo de la enfermedad (por ejemplo, cada 6 a 12 meses en enfermedad estable y cada 3 a 6 meses en enfermedad activa o con peor pronóstico).\n\n**Limitaciones:**\n\n- Pueden ser **estresantes o difíciles de completar** para algunos pacientes debido a síntomas como tos o disnea.  \n- No reflejan de forma completa la capacidad funcional para actividades diarias o el impacto subjetivo de la enfermedad.  \n- La interpretación puede verse afectada por otras manifestaciones extrapulmonares concomitantes de las ERAS (aunque esto es más una limitación para otras pruebas como la 6MWD).  \n- La evidencia disponible para su uso específico en este contexto es de **muy baja certeza**, lo que implica incertidumbre sobre la mejor frecuencia y la sensibilidad para detectar cambios clínicamente relevantes.\n\nEn resumen, las PFTs constituyen la herramienta fundamental y recomendada para monitorear la EPI en ERAS debido a su objetividad y practicidad, aunque presentan limitaciones relacionadas con la tolerabilidad de la prueba y la evidencia limitada que sustenta su uso óptimo en esta población.",
        "contexto": [
            "between rheumatology and pulmonology. Thus, some recommendations will comment on potential variations in practice between these specialties. For people with SARD-ILD, we conditionally recommend monitoring with PFTs. PFTs (spirometry, volumes, and DLCO) provide objective data that are helpful in following patients over time. Patients saw benefit in an objective test to help assess disease stability or progression. Although PFTs can reassure both patient and clinician when they are stable,",
            "<ul>\n<li>PFTs included spirometry, lung volumes, and DLCO. DLCO, diffusion capacity for carbon monoxide; HRCT chest, high-resolution computed tomography of the chest; IIM, idiopathic inflammatory myopathies; ILD, interstitial lung disease; MCTD, mixed connective tissue disease; PFT, pulmonary function test; RA, rheumatoid arthritis; SARD, systemic autoimmune rheumatic disease; SjD, Sjögren disease; SSc, systemic sclerosis; 6MWD, 6-minute walk test distance.</li>\n</ul>",
            "PFTs can reassure both patient and clinician when they are stable, patients commented that PFTs can also be stressful and difficult because of their symptoms of cough or 1 For people with SARD-ILD, we conditionally recommend monitoring with HRCT chest. Two observational studies and two post hoc analyses of the Scleroderma Lung Study (SLS) randomized controlled trial (RCT) contributed indirect evidence for this recommendation. For people with SARD-ILD, we conditionally recommend monitoring with",
            "on the panel routinely perform ambulatory desaturation testing in their offices. It is difficult to recommend a specific interval of ambulatory desaturation testing, and there is no evidence to support this guidance. DISCUSSION This guideline provides recommendations to clinicians for ILD screening and monitoring in people with RA, SSc, IIM, MCTD, and SjD. PFTs (including spirometry, lung volumes, and DLCO) and HRCT chest are conditionally recommended for the screening of ILD in people with",
            "perform PFTs, or those with associated pulmonary hypertension. For people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with bronchoscopy. Based on very low-certainty evidence from two observational studies, One retrospective observational (very low-certainty evidence) study provided indirect evidence for this recommendation. Suggestions for frequency of screening Evidence to support the frequency of testing was limited, The Core Team and Voting"
        ]
    },
    {
        "pregunta": "16. What criteria might prompt a clinician to perform HRCT in a patient with SARDs-ILD, despite the lack of specific guidance on routine frequency?",
        "respuesta": "Los criterios que podrían llevar a un clínico a realizar una tomografía computarizada de alta resolución (HRCT) de tórax en un paciente con enfermedad pulmonar intersticial (EPI) asociada a enfermedades reumáticas autoinmunes sistémicas (ERAS), pese a no existir una recomendación específica sobre la frecuencia rutinaria, incluyen:\n\n- **Indicaciones clínicas específicas**, como cambios en el cuadro sintomático (por ejemplo, empeoramiento de tos o disnea), que sugieran progresión o complicación de la EPI.  \n- **Resultados anormales o cambios significativos en pruebas de función pulmonar (PFTs)** que requieran confirmación o caracterización radiológica.  \n- **Presencia de factores de mal pronóstico o patrones radiológicos particulares** (por ejemplo, neumonía intersticial usual - UIP) que pueden requerir evaluación más detallada.  \n- **Incertidumbre diagnóstica o evaluación de la extensión y patrón de la EPI** para guiar decisiones terapéuticas.  \n- Situaciones donde la exploración física o estudios anteriores no sean concluyentes o tengan limitaciones para evaluar adecuadamente la enfermedad pulmonar.\n\nEn suma, la HRCT se usa como una prueba complementaria a las PFTs para el monitoreo y evaluación cuando está clínicamente indicada, adaptándose a la evolución y necesidades específicas de cada paciente.",
        "contexto": [
            "statement. HRCT chest; high-resolution computed tomography of the chest; ILD, interstitial lung disease; PICO, population, intervention, comparison, and outcomes; PFT, pulmonary function test; SARD, systemic autoimmune rheumatic disease; 6MWD, 6-minute walk test distance.</li>",
            "statement. HRCT chest, high-resolution computed tomography of the chest; ILD, interstitial lung disease; PICO, population, intervention, comparison and outcome; PFT, pulmonary function test; SARD, systemic autoimmune rheumatic disease; 6MWD, 6-minute walk test distance.</li>",
            "66% specific), despite very low certainty of evidence (one observational study), For people with SARDs at increased risk of developing ILD, we conditionally recommend screening with HRCT chest over history and physical examination or PFTs alone. Very low-certainty evidence suggests that the HRCT chest has a sensitivity of 95.7% and specificity of 63.8% for the detection of ILD (≥20% extent of lung involvement). Low-certainty evidence from five observational studies suggests that PFTs alone may",
            "with MCTD and prominent features of SSc or IIM may benefit from more frequent monitoring. For people with SARD-ILD, we do not provide guidance about frequency of routine HRCT chest for monitoring ILD but suggest HRCT chest when clinically indicated. There was hesitancy to recommend how frequently HRCT chest should be performed. HRCT chest is a complementary test to PFTs for the monitoring of ILD progression and may be specifically useful in cases in which coughing or other factors might affect",
            "2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases  National Scleroderma Foundation  Pulmonary Fibrosis Foundation  CAE  Boston University Medical Center  Johns Hopkins University School of Medicine  Global Healthy Living Foundation      F4AB96C66964635F924057BA1BB25AD2 10.1002/art.42860 Submitted for publication August 21, 2023;"
        ]
    },
    {
        "pregunta": "17. Why is chest radiography not recommended as a screening test for ILD in patients with SARDs?",
        "respuesta": "La radiografía de tórax **no se recomienda como prueba de tamizaje** para la enfermedad pulmonar intersticial (EPI) en pacientes con enfermedades reumáticas autoinmunes sistémicas (ERAS) porque presenta una **baja sensibilidad, estimada entre 58% y 64%**, lo que limita su utilidad para detectar de manera temprana y adecuada la EPI en esta población. Debido a esta baja capacidad para identificar la enfermedad de forma confiable, la guía la desaconseja de manera condicional para el tamizaje rutinario, favoreciendo en su lugar pruebas como las pruebas de función pulmonar (PFTs) y la tomografía computarizada de alta resolución (HRCT).",
        "contexto": [
            "evidence from five observational studies suggests that PFTs alone may be insufficient to detect ILD among patients with newly diagnosed SARDs. For people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with chest radiography. Three studies indicated a low sensitivity of chest radiography (58%-64%), limiting utility as a screening test for ILD. For people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with",
            "2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases  National Scleroderma Foundation  Pulmonary Fibrosis Foundation  CAE  Boston University Medical Center  Johns Hopkins University School of Medicine  Global Healthy Living Foundation      F4AB96C66964635F924057BA1BB25AD2 10.1002/art.42860 Submitted for publication August 21, 2023;",
            "2023 American College of Rheumatology (ACR) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease      AB9490E2CBB5C4579E5F0776547A04FE ACR Board of Directors on 12 August 2023. These recommendations are included in a full manuscript, pending peer review, which was submitted for publication in Arthritis & Rheumatology and Arthritis Care and Research.  Table 1. Summary of recommendations for screening of SARD-ILD Summary",
            "are conditionally recommended for the screening of ILD in people with these SARDs, whereas PFTs, HRCT chest, and ambulatory desaturation testing are conditionally recommended for the monitoring of people with SARD-ILD. There are limited to no roles for chest radiography, 6MWD, bronchoscopy, or surgical lung biopsy for the routine screening or monitoring of people with SARD-ILD. We provide guidance on the risk factors and frequency of testing to evaluate for the development of ILD in people with",
            "on the panel routinely perform ambulatory desaturation testing in their offices. It is difficult to recommend a specific interval of ambulatory desaturation testing, and there is no evidence to support this guidance. DISCUSSION This guideline provides recommendations to clinicians for ILD screening and monitoring in people with RA, SSc, IIM, MCTD, and SjD. PFTs (including spirometry, lung volumes, and DLCO) and HRCT chest are conditionally recommended for the screening of ILD in people with"
        ]
    },
    {
        "pregunta": "18. What screening method is conditionally recommended over history and physical examination alone for patients with SARDs at increased ILD risk?",
        "respuesta": "El método de tamizaje recomendado **de manera condicional sobre la historia clínica y el examen físico solamente** para pacientes con enfermedades reumáticas autoinmunes sistémicas (ERAS) con riesgo aumentado de enfermedad pulmonar intersticial (EPI) son las **pruebas de función pulmonar (PFTs)**, que incluyen espirometría, volúmenes pulmonares y difusión de monóxido de carbono (DLCO).\n\nEsto significa que, además de la evaluación clínica (historia y examen físico), se aconseja condicionalmente realizar PFTs para detectar precozmente la EPI en pacientes con factible riesgo aumentado, en el marco de una toma de decisiones compartida entre el médico y el paciente.\n\nPor el contrario, no se recomienda condicionalmente usar solo la historia clínica y el examen físico para descartar o tamizar EPI, dado que pueden ser insuficientes para una detección temprana. Tampoco se recomienda la radiografía de tórax para tamizaje debido a su baja sensibilidad.\n\nEn resumen:  \n**PFTs son el método condicionalmente recomendado complementario al interrogatorio y examen físico en pacientes con ERAS y riesgo aumentado de EPI.**",
        "contexto": [
            "2023 American College of Rheumatology (ACR) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease      AB9490E2CBB5C4579E5F0776547A04FE ACR Board of Directors on 12 August 2023. These recommendations are included in a full manuscript, pending peer review, which was submitted for publication in Arthritis & Rheumatology and Arthritis Care and Research.  Table 1. Summary of recommendations for screening of SARD-ILD Summary",
            "2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases  National Scleroderma Foundation  Pulmonary Fibrosis Foundation  CAE  Boston University Medical Center  Johns Hopkins University School of Medicine  Global Healthy Living Foundation      F4AB96C66964635F924057BA1BB25AD2 10.1002/art.42860 Submitted for publication August 21, 2023;",
            "|Recommendation: For patients with EGPA and high serum IgE levels who have experienced relapse with nonsevere disease manifestations (asthma and/or sinonasal disease) while receiving methotrexate, azathioprine, or mycophenolate mofetil, we conditionally recommend adding mepolizumab over adding omalizumab.|27|Very low|\n|Other considerations| | |",
            "(see ungraded position statement and recommendation on this topic). Recommendation: For patients with EGPA who have experienced relapse with nonsevere disease manifestations (asthma and/or sinonasal disease) while receiving methotrexate, azathioprine, or mycophenolate mofetil, we conditionally recommend adding mepolizumab over switching to another agent. For patients with EGPA with active asthma, inhaled therapies should be maximized prior to increasing systemic immunosuppressive therapy.",
            "by a greater number of randomized trials than are currently available in EGPA. All of the recommendations made for these 3 diseases are conditional, which indicates that there are settings in which the evidence is not strong or an alternative is a reasonable consideration. These recommendations should not be used by any agency to restrict access to therapy or require that certain therapies be utilized prior to other therapies. The physicians on the Voting Panel were primarily rheumatologists,"
        ]
    },
    {
        "pregunta": "19. Why might patients with Sjögren’s syndrome-associated ILD (SjD-ILD) require varied monitoring frequencies?",
        "respuesta": "Los pacientes con enfermedad pulmonar intersticial asociada al síndrome de Sjögren (SjD-EPI) podrían requerir frecuencias variables de monitoreo debido a la heterogeneidad en la progresión de la enfermedad y a la actividad clínica individual. La información señala que para las EPI asociadas a Artritis Reumatoide (AR), síndrome de Sjögren (SjD) y enfermedad mixta del tejido conectivo (EMTC), se sugiere realizar pruebas de función pulmonar (PFTs) para monitoreo con una frecuencia que puede variar entre cada 3 y 12 meses durante el primer año, ajustando la frecuencia posterior según si la enfermedad se mantiene estable o progresa.\n\nEsta variabilidad en el monitoreo busca adaptarse a la actividad y etapa de la EPI en cada paciente, permitiendo un seguimiento más estrecho en casos de enfermedad activa o progresiva y un control menos frecuente cuando la enfermedad está estable, siempre dentro de un marco de toma de decisiones compartida.\n\nEn resumen, la frecuencia variable responde a:\n\n- Diferencias en la actividad y progresión de la enfermedad pulmonar intersticial en pacientes con SjD.  \n- Necesidad de adaptar la frecuencia de seguimiento según la clínica, estudios funcionales y radiológicos.  \n- Balance entre detectar cambios tempranos y evitar pruebas innecesarias en enfermedad estable.",
        "contexto": [
            "instead. Some patients may need more frequent monitoring, especially if symptoms change, and these suggestions should not be used to inform reimbursement decisions. There is substantial clinical variation from patient to patient that may affect testing frequency. For people with IIM-ILD and SSc-ILD, we suggest PFTs for monitoring every 3 to 6 months for the first year, then less frequently once stable. More frequent monitoring is needed early in the course of disease and in patients with active",
            "There was no published evidence. The panel was not in favor of routine use of bronchoscopy for monitoring but recognized its utility in certain circumstances, such as in the evaluation of infection or alveolar hemorrhage. Suggestions for frequency of monitoring The Voting Panel decided not to provide firm recommendations for frequency of monitoring once an ILD diagnosis is made, but general guidance in the form of suggestions instead. Some patients may need more frequent monitoring, especially",
            "active underlying SARD warrant more frequent monitoring. Pulmonologists generally see more progressive than long-standing, stable disease and prefer more frequent monitoring. Similarly, the Patient Panel expressed that there is \"nothing worse than being missed\" and strongly preferred more frequent testing to be reassured that their disease is stable. Because the guideline's target population included people with SARDs who have stable ILD as well as those with progressive ILD, it was important",
            "between rheumatology and pulmonology. Thus, some recommendations will comment on potential variations in practice between these specialties. For people with SARD-ILD, we conditionally recommend monitoring with PFTs. PFTs (spirometry, volumes, and DLCO) provide objective data that are helpful in following patients over time. Patients saw benefit in an objective test to help assess disease stability or progression. Although PFTs can reassure both patient and clinician when they are stable,",
            "is needed early in the course of disease and in patients with active or progressive disease, and then every 6 to 12 months after the first year if the disease is stable. For people with long-standing SSc or IIM and prolonged stability of their ILD, we suggest less frequent monitoring. This range allows for flexibility. For people with RA-ILD, SjD-ILD, and MCTD-ILD, we suggest PFTs for monitoring every 3 to 12 months for the first year, then less frequently once stable. RA-ILD typically"
        ]
    },
    {
        "pregunta": "20. In which clinical scenarios is the 6MWD considered a useful marker for monitoring ILD progression?",
        "respuesta": "La prueba de la distancia caminada en 6 minutos (6MWD) **es útil como marcador para el monitoreo de la progresión de la enfermedad pulmonar intersticial (EPI) en escenarios clínicos específicos, tales como**:\n\n- La evaluación pretrasplante pulmonar, para valorar la elegibilidad y seguimiento del paciente.  \n- Pacientes con hipertensión pulmonar asociada, donde ayuda a evaluar la capacidad funcional y respuesta al tratamiento.  \n- Aquellos pacientes que no pueden realizar pruebas de función pulmonar (PFTs), sirviendo como alternativa funcional para valorar la progresión de la enfermedad.\n\nEn pacientes con EPI asociada a enfermedades reumáticas autoinmunes sistémicas (ERAS), la 6MWD está condicionadamente recomendada **en contra para el monitoreo rutinario**, debido a que:\n\n- No refleja adecuadamente los síntomas ni la capacidad funcional para actividades diarias.  \n- Puede verse afectada por manifestaciones extrapulmonares como artritis o enfermedad cardíaca, dificultando la interpretación específica para EPI.\n\nPor lo tanto, la utilidad de la 6MWD está mayormente reservada para los contextos mencionados, no para el seguimiento habitual de la EPI en la población con ERAS.",
        "contexto": [
            "did not reflect activities of daily living or function in daily life. If patients without confounding health factors can perform the test, it can be a useful marker to follow disease progression. 6MWD is important in the monitoring of patients pre-lung transplantation, those with pulmonary hypertension, and those unable to perform PFTs. For people with SARD-ILD, we conditionally recommend against monitoring with bronchoscopy. There was no published evidence. The panel was not in favor of",
            "risk of developing ILD, we conditionally recommend against screening with 6MWD. The Literature Review Team found no published evidence regarding 6MWD as a screening test for ILD. Rather, it is used for evaluation for lung transplantation and for monitoring in those with pulmonary hypertension. In people with SARDs, the 6MWD can be impacted by other SARD manifestations that affect mobility including arthritis and cardiac disease. The Patient Panel felt the 6MWD frequently did not reflect",
            "(73.6%) of chest radiography relative to HRCT chest for identifying ILD among patients with inflammatory rheumatic diseases. For people with SARD-ILD, we conditionally recommend against monitoring with 6MWD. There was no evidence to support or oppose using 6MWD in the monitoring of people with SARD-ILD. 6MWD can be impacted by other health factors, such as arthritis and cardiac disease. Patients reported that 6MWD often did not reflect activities of daily living or function in daily life. If",
            "disease. The Patient Panel felt the 6MWD frequently did not reflect symptoms and may not reflect functional status or ability to perform activities of daily living. For people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with ambulatory desaturation testing. The Literature Review Team found no published evidence regarding the use of ambulatory desaturation testing as a screening test for ILD in SARDs. Given feasibility concerns in rheumatology",
            "on the panel routinely perform ambulatory desaturation testing in their offices. It is difficult to recommend a specific interval of ambulatory desaturation testing, and there is no evidence to support this guidance. DISCUSSION This guideline provides recommendations to clinicians for ILD screening and monitoring in people with RA, SSc, IIM, MCTD, and SjD. PFTs (including spirometry, lung volumes, and DLCO) and HRCT chest are conditionally recommended for the screening of ILD in people with"
        ]
    }
]